This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Ireland, Israel, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa

Active ingredients

The drug NOVOMIX-30 contains one active pharmaceutical ingredient (API):

1 Insulin aspart

The blood glucose lowering effect of insulin aspart is due to the facilitated uptake of glucose following binding of insulin to receptors on muscle and fat cells and to the simultaneous inhibition of glucose output from the liver. Insulin aspart produces a more rapid onset of action compared to soluble human insulin, together with a lower glucose concentration, as assessed within the first four hours after a meal. Insulin aspart has a shorter duration of action compared to soluble human insulin after subcutaneous injection.

Read about Insulin aspart

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
A10AD05 Insulin aspart A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10A Insulins and analogues → A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting
Discover more medicines within A10AD05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: AU Pharmaceutical Benefits Scheme Identifier(s): 12238D, 8609D
Country: BR Câmara de Regulação do Mercado de Medicamentos Identifier(s): 526602001159415, 526602002155316
Country: CA Health Products and Food Branch Identifier(s): 02265435
Country: EE Ravimiamet Identifier(s): 1084788, 1084823, 1214468, 1214479, 1523786
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 00142009, 00142015, 00142021
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 001490, 006024
Country: FR Base de données publique des médicaments Identifier(s): 61693569, 64239493, 67832552, 68182431
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 143813, 143865, 201635, 32773, 32781, 376949, 376952, 379926
Country: HK Department of Health Drug Office Identifier(s): 52604, 61546
Country: IE Health Products Regulatory Authority Identifier(s): 64275, 68927, 68930, 76140
Country: IL מִשְׂרַד הַבְּרִיאוּת Identifier(s): 4621
Country: LT Valstybinė vaistų kontrolės tarnyba Identifier(s): 1004366, 1008620, 1029898, 1029899, 1059246, 1059247, 1059248
Country: NL Z-Index G-Standaard Identifier(s): 14719509, 14719517
Country: NL Z-Index G-Standaard, PRK Identifier(s): 121320, 121339, 121347, 65749
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 10731, 9745
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100102170, 100108906
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W08254001, W08254002, W08973001, W08973002
Country: SG Health Sciences Authority Identifier(s): 12190P, 15480P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 5993082
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699676950690, 8699676950706
Country: ZA Health Products Regulatory Authority Identifier(s): 35/21.1/0031

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.